Literature DB >> 20471695

Earliest functional declines in Huntington disease.

Leigh J Beglinger1, Justin J F O'Rourke, Chiachi Wang, Douglas R Langbehn, Kevin Duff, Jane S Paulsen.   

Abstract

We examined the gold standard for Huntington disease (HD) functional assessment, the Unified Huntington's Disease Rating Scale (UHDRS), in a group of at-risk participants not yet diagnosed but who later phenoconverted to manifest HD. We also sought to determine which skill domains first weaken and the clinical correlates of declines. Using the UHDRS Total Functional Capacity (TFC) and Functional Assessment Scale (FAS), we examined participants from Huntington Study Group clinics who were not diagnosed at their baseline visit but were diagnosed at a later visit (N=265). Occupational decline was the most common with 65.1% (TFC) and 55.6% (FAS) reporting some loss of ability to engage in their typical work. Inability to manage finances independently (TFC 49.2%, FAS 35.1%) and drive safely (FAS 33.5%) were also found. Functional decline was significantly predicted by motor, cognitive, and depressive symptoms. The UHDRS captured early functional losses in individuals with HD prior to formal diagnosis, however, fruitful areas for expanded assessment of early functional changes are performance at work, ability to manage finances, and driving. These are also important areas for clinical monitoring and treatment planning as up to 65% experienced loss in at least one area prior to diagnosis. Copyright 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20471695      PMCID: PMC3629818          DOI: 10.1016/j.psychres.2010.04.030

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  15 in total

1.  Clinical markers of early disease in persons near onset of Huntington's disease.

Authors:  J S Paulsen; H Zhao; J C Stout; R R Brinkman; M Guttman; C A Ross; P Como; C Manning; M R Hayden; I Shoulson
Journal:  Neurology       Date:  2001-08-28       Impact factor: 9.910

2.  Behavioural abnormalities contribute to functional decline in Huntington's disease.

Authors:  J M Hamilton; D P Salmon; J Corey-Bloom; A Gamst; J S Paulsen; S Jerkins; M W Jacobson; G Peavy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

3.  Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity.

Authors:  Carissa Nehl; Jane S Paulsen
Journal:  J Nerv Ment Dis       Date:  2004-01       Impact factor: 2.254

4.  Huntington disease: clinical care and evaluation.

Authors:  I Shoulson; S Fahn
Journal:  Neurology       Date:  1979-01       Impact factor: 9.910

5.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

6.  Rate of functional decline in Huntington's disease. Huntington Study Group.

Authors:  K Marder; H Zhao; R H Myers; M Cudkowicz; E Kayson; K Kieburtz; C Orme; J Paulsen; J B Penney; E Siemers; I Shoulson
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

7.  Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.

Authors: 
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

8.  Cognitive and motor correlates of everyday functioning in early Huntington's disease.

Authors:  J C Rothlind; F W Bylsma; C Peyser; S E Folstein; J Brandt
Journal:  J Nerv Ment Dis       Date:  1993-03       Impact factor: 2.254

9.  Evidence for specific cognitive deficits in preclinical Huntington's disease.

Authors:  A D Lawrence; J R Hodges; A E Rosser; A Kershaw; C ffrench-Constant; D C Rubinsztein; T W Robbins; B J Sahakian
Journal:  Brain       Date:  1998-07       Impact factor: 13.501

10.  Detection of Huntington's disease decades before diagnosis: the Predict-HD study.

Authors:  J S Paulsen; D R Langbehn; J C Stout; E Aylward; C A Ross; M Nance; M Guttman; S Johnson; M MacDonald; L J Beglinger; K Duff; E Kayson; K Biglan; I Shoulson; D Oakes; M Hayden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12-20       Impact factor: 10.154

View more
  51 in total

1.  Challenges assessing clinical endpoints in early Huntington disease.

Authors:  Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

3.  Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Authors:  Elissa J Donzis; Ana María Estrada-Sánchez; Tim Indersmitten; Katerina Oikonomou; Conny H Tran; Catherine Wang; Shahrzad Latifi; Peyman Golshani; Carlos Cepeda; Michael S Levine
Journal:  Cereb Cortex       Date:  2020-04-14       Impact factor: 5.357

4.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Authors:  Jane S Paulsen; Jeffrey D Long; Christopher A Ross; Deborah L Harrington; Cheryl J Erwin; Janet K Williams; Holly James Westervelt; Hans J Johnson; Elizabeth H Aylward; Ying Zhang; H Jeremy Bockholt; Roger A Barker
Journal:  Lancet Neurol       Date:  2014-11-03       Impact factor: 44.182

5.  Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Janis M Miyasaki
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

6.  Regional atrophy associated with cognitive and motor function in prodromal Huntington disease.

Authors:  Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen
Journal:  J Huntingtons Dis       Date:  2013

7.  Movement sequencing in Huntington disease.

Authors:  Nellie Georgiou-Karistianis; Jeffrey D Long; Spencer G Lourens; Julie C Stout; James A Mills; Jane S Paulsen
Journal:  World J Biol Psychiatry       Date:  2014-03-28       Impact factor: 4.132

8.  Clinical predictors of driving status in Huntington's disease.

Authors:  Leigh J Beglinger; Luke Prest; James A Mills; Jane S Paulsen; Megan M Smith; Pedro Gonzalez-Alegre; Kelly C Rowe; Peggy Nopoulos; Ergun Y Uc
Journal:  Mov Disord       Date:  2012-06-28       Impact factor: 10.338

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 10.  Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Barbara S Koppel; John C M Brust; Terry Fife; Jeff Bronstein; Sarah Youssof; Gary Gronseth; David Gloss
Journal:  Neurology       Date:  2014-04-29       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.